文献速递消化道肿瘤放疗姑息放疗与转移瘤

直肠癌全程新辅助治疗:现状与未来方向

Total neoadjuvant therapy for rectal cancer: where are we now, where do we go?
PubMed 文献 · Clin Transl Radiat Oncol · 2026-08-07

全程新辅助治疗(TNT)指在短程放疗(SCRT)或放化疗(CRT)基础上加入完整疗程的术前全身治疗,可为CRT前诱导化疗或SCRT/CRT后巩固化疗,随后行全直肠系膜切除术(TME)。随机试验显示,与常规新辅助放化疗加手术±辅助化疗相比,TNT可提高病理完全缓解率并显著改善无病生存期。TNT日益被视为首选策略,尤其适用于MRI定义的高危直肠癌患者。

要点

  • 随机试验证实TNT较新辅助放化疗改善病理完全缓解率与无病生存期。
  • MRI定义的高危直肠癌(如cT4、cN2、mrCRM+、EMVI+、侧方淋巴结受累)更适合TNT。
  • TNT后临床完全缓解率更高,器官保留(观察等待)策略日益受青睐。

核心结论

  • 随机试验显示TNT较新辅助放化疗加手术±辅助化疗提高病理完全缓解率并显著改善无病生存期,日益被视为首选策略,尤其适用于MRI定义的高危直肠癌患者。

研究设计与样本

  • 本文为综述,汇总TNT相关随机试验及正在进行的临床试验(如ACO/ARO/AIO 18.1、JANUS、ENSEMBLE、TRESOR、STELLAR II)。

主要发现

  • TNT指在SCRT(5×5 Gy)或CRT基础上加入完整疗程术前全身治疗,可为CRT前诱导化疗或SCRT/CRT后巩固化疗,随后行TME手术。
  • 随机试验证实TNT较新辅助放化疗加手术±辅助化疗提高病理完全缓解率并显著改善无病生存期。
  • TNT后临床完全缓解率更高,器官保留(观察等待)策略日益受青睐并在ongoing试验中持续优化。

关键数值与推荐

  • TNT适用于MRI定义的高危直肠癌,包括cT4、cN2、mrCRM+、EMVI+及侧方淋巴结受累。
  • SCRT方案为5×5 Gy。

临床怎么用

  • 对MRI定义的高危直肠癌患者可优先考虑TNT策略。
  • TNT后达到临床完全缓解者可考虑器官保留(观察等待)策略,但需在临床试验框架下持续优化。

局限性

  • 最佳放疗方案(SCRT vs CRT)、治疗顺序(诱导 vs 巩固)、化疗周期数、放疗剂量递增策略、TNT及手术后是否需辅助化疗、免疫治疗在dMMR/pMMR疾病中的作用等关键问题尚待明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Total neoadjuvant therapy (TNT) refers to the addition of an entire course of preoperative systemic therapy to short-course radiotherapy (SCRT; 5 × 5 Gy) or chemoradiation (CRT), either as induction chemotherapy before CRT or as consolidation therapy after SCRT/CRT, followed by total mesorectal excision (TME) surgery. Randomized trials have demonstrated improved pathological complete response rates and a significant improvement in disease-free survival with TNT compared to neoadjuvant CRT plus surgery with or without adjuvant chemotherapy. TNT is increasingly considered the preferred treatment strategy, especially for patients with MRI-defined high-risk rectal cancer. (such as cT4, cN2, Magnetic Resonance Circumferential Resection Margins Positive (mrCRM+), Extramural Vascular Invasion Positive (EMVI+), lateral lymph node involvement). Key questions remain, including the optimal RT regimen (SCRT vs. CRT), the sequence of treatment components (induction vs. consolidation therapy), the number of chemotherapy cycles, RT-dose escalation strategies, the need of adjuvant chemotherapy after TNT and surgery, and the role of immunotherapy in both mismatch repair-deficient and mismatch repair-proficient (dMMR/pMMR) disease. Due to the higher rates of clinical complete response achieved with TNT, organ-preserving ("watch-and-wait") strategies are increasingly favored and continue to be refined in ongoing clinical trials (e.g., ACO/ARO/AIO 18.1, JANUS, ENSEMBLE, TRESOR, and STELLAR II).

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fleischmann M, Kristen A, Diefenhardt M, et al. Total neoadjuvant therapy for rectal cancer: where are we now, where do we go? Clin Transl Radiat Oncol. 2026. PMID: 42604092. doi:10.1016/j.ctro.2026.101254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。